Global Biobanking Market Poised to Reach $12.38 Billion by 2031

The growth trajectory is largely propelled by the increasing complexity of cell and gene therapy development, which demands rigorous collection, preservation, and management of high-quality biological samples. As research pipelines expand, there is a heightened need for standardized storage and integrated tracking systems to support clinical development and therapeutic manufacturing.

Strategic investments currently favor companies that provide end-to-end solutions rather than traditional physical storage. Industry players are increasingly integrating AI-powered informatics and automated platforms into their workflows to bridge the gap between stored biospecimens and actionable genomic data. Recent activity highlights this shift, such as QIAGEN’s acquisition of Genoox to bolster AI-enabled genomic interpretation and Azenta’s purchase of UK Biocentre to expand its European biorepository and high-throughput processing capabilities.

North America remains the dominant regional player, holding approximately 43.3% of the market share as of 2025. This leadership is supported by a robust ecosystem of biomedical research and early adoption of advanced cryopreservation and digital management technologies. While the market remains fragmented, the top five firms currently control roughly half of the product segment, reflecting a competitive landscape where consolidation is expected to continue as providers seek to offer comprehensive, automated sample-to-data services.